1/20/2021 9:01:33 AM
Adamis Announces IND Submission To FDA For Tempol For Treatment Of COVID-19
12/1/2020 9:17:43 AM
Adamis Intends To Address All Deficiencies Raised In ZIMHI CRL And Request FDA Approve NDA
9/18/2020 9:14:15 AM
Adamis Prices Public Offering Of 16.13 Mln Shares At $0.62 Per Share
8/14/2020 9:08:52 AM
Adamis Reports Pre-IND Feedback From FDA Enabling Advancement Of Tempol